Identification of single-nucleotide polymorphisms of the human neurokinin 1 receptor gene and pharmacological characterization of a Y192H variant

Pharmacogenomics Journal

Volumn 4, Issue 6, 2004, Pages 394-402

  Randolph, G P ^a   Simon, J S ^a   Arreaza, M G ^a   Qiu, P ^a   Lachowicz, J E ^a   Duffy, Ruth A ^a  

^a Discovery Technology   (Finland)

Author keywords

Depression; Hemokinin 1; Mutation; Pharmacogenomics; Substance P; Tachykinins

Indexed keywords

2 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 4 (3 OXO 1,2,4 TRIAZOL 5 YLMETHYL) 3 PHENYLMORPHOLINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; APREPITANT; CALCIUM; DNA; HISTIDINE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; TYROSINE; VOFOPITANT;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG RECEPTOR BINDING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; INTERNALIZATION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN VARIANT; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS;

ALLELES; AMINO ACID SUBSTITUTION; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE FREQUENCY; HISTIDINE; HUMANS; PEPTIDE FRAGMENTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; RECEPTORS, NEUROKININ-1; SUBSTANCE P; TYROSINE; VARIATION (GENETICS);

EMESIS;

EID: 10044258462     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500276     Document Type: Article

References (34)

1. Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol 1999; 375 51-60.
2. Duffy RA, Hedrick JA, Randolph G, Morgan CA, Cohen-Williams ME, Vassileva G et al. Centrally administered hemokinin-1 (HK1), a neurokinin NK1 receptor agonist, produces substance p-like behavioral effects in mice and gerbils. Neurophormacology 2003; 45: 242-250.
3. Rupniak NMJ, Kramer MS. Discovery of the anti-depressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 1999; 20: 485-490.
4. Gardner CJ, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ et al. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Peptides 1996; 65: 45-53.
5. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-1645.
6. Gesztesi Z, Scuderi PE, White PF, Wright W, Wender RH, D'angelo R et al. Substance P (Neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures. Anesthesiology 2000; 93: 931-937.
7. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A et al. Reduction of cisplatin-induced emesis by a selective nurokinin-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 1999; 340: 1926-1928.
8. Poli-Bigelli S, Rodrigues-Pereira J, Caricles AD, Julie Ma G, Eldridge K, Hippie A et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090-3098.
9. Roses AD. Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov 2002; 1: 541-549.
10. Steen VM, Lovlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK. The polymorphic inositol polyphospahte 1-phosphatase gene as a candidate for pharmocogenetic predicition of lithium-responsive manic depressive illness. Pharmacogenetics 1998; 8: 259-268.
11. Green SA, Rathz DA, Schuster AJ, Liggett SB. The Ile164 beta(2)-adrenoceptor polymorphism alters salmerol exosite binding and conventional agonist coupling to G(s). Eur J Pharmocol 2001; 421 141-147.
12. Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA et al. Meta-analysis of studies on genetic variation in 5-HT2A receptor and clozapine response. Schizophr Res 1998; 32: 93-99.
13. Güzey C, Spigset O. Genotyping of drug targets: a method to predict adverse drug reactions. Drug Saf 2002; 25: 553-560.
14. Fong TM, Yu H, Strader CD. Molecular basis for the species selectivity of the neurokinin-1 receptor antagonist CP-96345. J Biol Chem 1992; 267: 25668-25671.
15. Halushka MK, Fan J-B, Bentley K, Hsie L, Shen N, Weder A et al. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 1999; 22: 239-247.
16. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999; 22: 231-238.
17. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409 928-933.
18. McLean S. Nonpeptide antagonists of the NK1 tachykinin receptor. Med Res Rev 1996; 16: 297-317.
19. Greenfeder S, Cheewatrakoolpong B, Anthes J, Billah M, Egan RW, Brown JE et al. Two related neurokinin-1 receptor antagonist have overlapping but different binding sites. Bioorg Med Chem 1998; 6: 189-194.
20. Greenfeder S, Cheewatrakoolpong B, Billah M, Egan RW, Keene E, Murgolo NJ et al. The neurokinin-1 and neurokinin-2 receptor binding sites of MDL103,392 differ. Bioorg Med Chem 1999; 7: 2867-2876.
21. McConalogue K, Dery O, Lovett M, Wong H, Walsh JH, Grady EF et al. Substance P-induced trafficking of β-arrestins: The role of β-arrestins in endocytosis of the neurokinin-1 receptor. J Biol Chem 1999; 274: 16257-16268.
22. Tribut O, Lessard Y, Reymann JM, Allain H, Bentué-Ferrer D. Pharmacogenomics. Med Sci Monit 2002; 8: RA152-RA163.
23. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 28 487-491.
24. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 varients in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-295.
25. Ingelman-Sundberg M, Oscarson M, McIellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342-349.
26. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari Israel E et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22: 168-170.
27. Baumgart D, Naber C, Haude M, Oldenburg O, Erbel R, Heusch G et al. G protein beta3 subunit 825T allele and enhanced coronary vasocontriction on alpha(2)-adrenoceotir activation. Circ Res 1999; 85: 965-969.
28. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508-511.
29. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105-107.
30. Nickerson DA, Kolker N, Taylor SL, Rieder MJ. Sequence-based detection of single nucleotide polymorphisms. Methods Mol Biol 2001; 175: 29-35.
31. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997; 25: 2745-2751.
32. Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Hum Mutat 1998; 11: 1-3.
33. 50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-3108.
34. Schild HO. Drug Antagonism and pAx. Pharmacol Rev 1957; 9: 242-246.